Anika Therapeutics, Inc. (ANIK) vs BioAge Labs Inc. (BIOA)
A side-by-side comparison of Anika Therapeutics, Inc. and BioAge Labs Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ANIK
Anika Therapeutics, Inc.
$19.17HealthcareDelayed quote: Oct 6, 2026, 2:48 PM EDT
BIOA
BioAge Labs Inc.
$6.13HealthcareDelayed quote: Oct 6, 2026, 2:50 PM EDT
Total return — ANIK vs BIOA
growth of $100 · dividends reinvested · last 2yANIK -21.7% (-11.5%/yr)BIOA -65.3% (-41.1%/yr)ANIK compounded faster over this window
ANIK BIOA
ANIK vs BIOA: by the numbers
- •ANIK is the larger company ($257M vs $231M market cap).
- •Both run net losses; ANIK's is the smaller (-3.14% vs -912.25% net margin).
Metrics side by side
Valuation
| Metric | ANIK | BIOA |
|---|---|---|
| Forward P/E | 18.26 | N/A |
| P/S ratio | 2.13 | 22.29 |
| P/B ratio | 1.87 | 0.62 |
| EV / EBITDA | 474.34 | N/A |
| FCF yield | 0.22% | N/A |
Profitability
| Metric | ANIK | BIOA |
|---|---|---|
| Gross margin | 62.16% | 99.39% |
| Operating margin | -4.24% | -1026.28% |
| Net margin | -3.14% | -912.25% |
| ROE | -2.76% | -25.20% |
| ROIC | -3.17% | -28.14% |
Growth (annualized)
| Metric | ANIK | BIOA |
|---|---|---|
| Revenue CAGR (5Y) | -2.48% | N/A |
| FCF CAGR (5Y) | -39.38% | N/A |
| Total return CAGR (5Y) | -13.40% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.